Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury

Stem Cells Translational Medicine

Volumn 2, Issue 10, 2013, Pages 731-744

  Sontag, Christopher J ^a,b   Nguyen, Hal X ^a,b   Kamei, Noriko ^a,b   Uchida, Nobuko ^c   Anderson, Aileen J ^a,b   Cummingsa, Brian J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c StemCells Inc   (United States)

Author keywords

Differentiation; Immunosuppression; Neural stem cell; Proliferation; Spinal cord injury; Stem cell transplantation

Indexed keywords

BETA TUBULIN; BROXURIDINE; CD4 ANTIBODY; CYCLOSPORIN A; DOUBLECORTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOSUPPRESSIVE AGENT; IONOMYCIN; RAPAMYCIN; STAUROSPORINE; TACROLIMUS;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CONTUSION; CYTOTOXICITY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; SPINAL CORD INJURY;

ANIMALIA; MAMMALIA; MUS; RODENTIA;

EID: 84880225080     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0175     Document Type: Article

References (62)

1. Lomax GP, Hall ZW, Lo B. Responsible oversight of human stem cell research: The California Institute for Regenerative Medicine's medical and ethical standards. PLoS Med 2007;4:e114.
2. Chidgey AP, Boyd RL. Immune privilege for stem cells: Not as simple as it looked. Cell Stem Cell 2008;3:357-358.
3. Chidgey AP, Layton D, Trounson A et al. Tolerance strategies for stem-cell-based therapies. Nature 2008;453:330-337.
4. Borel JF, Feurer C, Gubler HU et al. Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 1976;6: 468-475.
5. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-1255.
6. Aramburu J, Heitman J, Crabtree GR. Calcineurin: A central controller of signalling in eukaryotes. EMBO Rep 2004;5:343-348.
7. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-726.
8. Hoeffer CA, Klann E. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 2010;33:67-75.
9. Anderson AJ, Sontag CJ, Haus DL et al. Achieving stable human stem cell engraftment and survival in the CNS: Is the future of regenerative medicine immunodeficient? Regen Med 2011;6:367-406.
10. Ideguchi M, Shinoyama M, Gomi M, et al. Immune or inflammatory response by the host brain suppresses neuronal differentiation of transplanted ES cell-derived neural precursor cells. J Neurosci Res 2008;86:1936-1943.
11. Uchida N, Buck DW, He D et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97: 14720-14725.
12. Cummings BJ, Uchida N, Tamaki SJ et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci USA 2005;102: 14069-14074.
13. Salazar DL, Uchida N, Hamers FP et al. Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS One 2010;5:e12272.
14. Hooshmand MJ, Sontag CJ, Uchida N et al. Analysis of host-mediated repair mechanisms after human CNS-stem cell transplantation for spinal cord injury: Correlation of engraftment with recovery. PLoS One 2009;4: e5871.
15. Piltti KM, Salazar DL, Uchida N et al. Safety of epicenter versus intact parenchyma as a transplantation site for human neural stem cells for spinal cord injury therapy. Stem Cells Translational Medicine 2013;2:204-216.
16. Azzola A, Havryk A, Chhajed P et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004;77: 275-280.
17. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2:374-384.
18. Piltti KM, Haus DL, Do E et al. Computer-Aided 2D and 3D quantification of human stem cell fate from in vitro samples using Volocity high performance image analysis software. Stem Cell Res 2011;7:256-263.
19. Durakovic N, Radojcic V, Powell J et al. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versusleukemia reactivity. Transplantation 2007;83: 631-640.
20. Karimi-Abdolrezaee S, Eftekharpour E, Wang J et al. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 2006;26:3377-3389.
21. Yan J, Xu L, Welsh AM et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006;24:1976-1985.
22. Basso DM, Fisher LC, Anderson AJ et al. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 2006;23:635-659.
23. Armstrong RJ, Svendsen CN. Neural stem cells: From cell biology to cell replacement. Cell Transplant 2000;9:139-152.
24. Chehrehasa F, Meedeniya AC, Dwyer P et al. EdU, a new thymidine analogue for labelling proliferating cells in the nervous system. J Neurosci Methods 2009;177:122-130.
25. Magnon C, Lucas D, Frenette PS. Trafficking of stem cells. Methods Mol Biol 2011;750: 3-24.
26. Hayashi Y, Shumsky JS, Connors T et al. Immunosuppression with either cyclosporine a or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury. J Neurotrauma 2005;22:1267-1281.
27. Ibarra A, Reyes J, Martinez S et al. Use of cyclosporin-A in experimental spinal cord injury: Design of a dosing strategy to maintain therapeutic levels. J Neurotrauma 1996;13: 569-572.
28. Liu Y, Himes BT, Murray M, et al. Grafts of BDNF-producing fibroblasts rescue axotomized rubrospinal neurons and prevent their atrophy. Exp Neurol 2002;178:150-164.
29. Liu Y, Kim D, Himes BT et al. Transplants of fibroblasts genetically modified to express BDNF promote regeneration of adult rat rubrospinal axons and recovery of forelimb function. J Neurosci 1999;19:4370-4387.
30. Hofstetter CP, Holmstrom NA, Lilja JA et al. Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci 2005;8:346-353.
31. Macias MY, Syring MB, Pizzi MA et al. Pain with no gain: Allodynia following neural stem cell transplantation in spinal cord injury. Exp Neurol 2006;201:335-348.
32. Mammucari C, Tommasi di Vignano A, Sharov AA et al. Integration of Notch 1 and calcineurin/ NFAT signaling pathways in keratinocyte growth and differentiation control. Dev Cell 2005;8:665-676.
33. Kageyama R, Ohtsuka T, Shimojo H et al. Dynamic regulation of Notch signaling in neural progenitor cells. Curr Opin Cell Biol 2009;21: 733-740.
34. Guo J, Zeng Y, Liang Y et al. Cyclosporine affects the proliferation and differentiation of neural stem cells in culture. Neuroreport 2007; 18:863-868.
35. Hunt J, Cheng A, Hoyles A et al. Cyclosporin A has direct effects on adult neural precursor cells. J Neurosci 2010;30:2888-2896.
36. Sunayama J, Sato A, Matsuda K et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 2010;12:1205-1219.
37. Zhuang W, Li B, Long L et al. Induction of autophagy promotes differentiation of gliomainitiating cells and their radiosensitivity. Int J Cancer 2011;129:2720-2731.
38. Magri L, Cambiaghi M, Cominelli M, et al. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell 2011;9:447-462.
39. Mittal N, Voldman J. Nonmitogenic survival-enhancing autocrine factors including cyclophilin A contribute to density-dependent mouse embryonic stem cell growth. Stem Cell Res 2011;6:168-176.
40. Gualco E, Urbanska K, Perez-Liz G et al. IGF-IR-dependent expression of Survivin is required for T-antigen-mediated protection from apoptosis and proliferation of neural progenitors. Cell Death Differ 2010;17:439-451.
41. Li M, Zhai Q, Bharadwaj U et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006;106:2284-2294.
42. Yang H, Chen J, Yang J et al. Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun 2007;361:763-767.
43. Chen J, Zheng XF, Brown EJ et al. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 1995;92:4947-4951.
44. Dowling RJ, Topisirovic I, Fonseca BD et al. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 2010; 1804:433-439.
45. Greenberger S, Yuan S, Walsh LA et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011; 131:2467-2476.
46. Bavetta S, Hamlyn PJ, Burnstock G et al. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: Neuroprotection and local regeneration. Exp Neurol 1999;158:382-393.
47. Ibarra A, Correa D, Willms K et al. Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury. Brain Res 2003; 979:165-178.
48. Ibarra A, Diaz-Ruiz A. Protective effect of cyclosporin-A in spinal cord injury: An overview. Curr Med Chem 2006;13:2703-2710.
49. Platz KP, Mueller AR, Jonas S et al. Toxicity versus rejection: Or why conversions between cyclosporine A and FK506 were performed after liver transplantation. Clin Transplant 1995;9:146-154.
50. Rabchevsky AG, Fugaccia I, Sullivan PG et al. Cyclosporin A treatment following spinal cord injury to the rat: Behavioral effects and stereological assessment of tissue sparing. J Neurotrauma 2001;18:513-522.
51. Sakamoto Y, Makuuchi M, Harihara Y et al. Correlation between neurotoxic events and intracerebral concentration of tacrolimus in rats. Biol Pharm Bull 2000;23:1008-1010.
52. Sulaiman OA, Voda J, Gold BG et al. FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic Schwann cell denervation. Exp Neurol 2002; 175:127-137.
53. Voda J, Yamaji T, Gold BG. Neuroimmunophilin ligands improve functional recovery and increase axonal growth after spinal cord hemisection in rats. J Neurotrauma 2005;22: 1150-1161.
54. Wang MS, Zeleny-Pooley M, Gold BG. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J Pharmacol Exp Ther 1997;282:1084-1093.
55. Yang RK, Lowe JB 3rd, Sobol JB et al. Dose-dependent effects of FK506 on neuroregeneration in a rat model. Plast Reconstr Surg 2003;112:1832-1840.
56. Lampen A, Christians U, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23:1315-1324.
57. Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008;5:e8.
58. Murakami Y, Takamatsu H, Noda A et al. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. J Nucl Med 2004;45:1946-1949.
59. Sakamoto Y, Makuuchi M, Harihara Y et al. Higher intracerebral concentration of tacrolimus after intermittent than continuous administration to rats. Liver Transpl 2001;7:1071-1076.
60. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004;4:97-107.
61. Serkova N, Hausen B, Berry GJ et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine. J Pharmacol Exp Ther 2000;294:323-332.
62. Willerth SM, Sakiyama-Elbert SE. Cell therapy for spinal cord regeneration. Adv Drug Deliv Rev 2008;60:263-276.